Appointment of Non-Executive Director

October 23rd, 2012

For immediate release

23 October 2012

Biosensia appoints James D. Merselis as Non-Executive Director

Dublin, 23 October 2012 … Biosensia ltd., a point of care diagnostics Company, today announces the appointment of James D. Merselis as Non-Executive Director.

Jim is currently a non-executive director at Trinity Biotech (NASDAQ: TRIB) and a consultant to healthcare diagnostics companies. He was formerly President and CEO of ITC Nexus Dx, Inc, a privately held diagnostics company working to improve patient care by providing rapid and reliable Point-of-Care medical test information. Prior to this, he served as President and CEO of Alverix, Inc, a privately held company developing portable medical diagnostic instruments.

Previous roles included, President and CEO of HemoSense Inc, (AMEX: HEM), President and CEO of Micronics, and a number of positions with Boehringer Mannheim Diagnostics (now Roche Diagnostics).

Diarmuid Flavin, CEO of Biosensia ltd., said: “Jim will make an excellent addition to the board at Biosensia. He has a wealth of experience in the diagnostics and point of care in particular and as we progress towards the commercialization of RapiPlex, his skills and experience will be invaluable.”

Jim Merselis added: “I am very pleased to be joining Biosensia at this exciting time. The company has developed an excellent product with RapiPlex, and I look forward to helping steer the company to success in the point of care market.”

Over the past year, Biosensia has hit a number of important milestones. The company raised €1.2 million in November 2011, and July 2012 saw the company showcase the RapiPlex platform for the first time at the AACC annual meeting.

-ends-

For further information, please contact:

Tony Stephenson

PR Consultant

Tel: +44 (0)7899 796655

Email: anthonytstephenson@gmail.com

About Biosensia

Biosensia is an in vitro diagnostics company, focused on developing next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex, a rapid, novel, multiplexing POC in vitro diagnostics platform, which can be used for a wide range of diagnostic applications. RapiPlex is suitable for use in all immunoassay formats and for multiple POC applications including medical, environmental, food safety and security. RapiPlex is suitable for use with a variety of small and large sample sizes and types including whole blood, serum, plasma, saliva and urine. Biosensia collaborates with healthcare companies to develop point of care diagnostics products. Biosensia is an independent, venture capital funded company based in the Nova UCD incubation centre at University College Dublin, Ireland.

www.biosensia.com